Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Mohamed Hassan Sayegh, M.D.

Co-Author

This page shows the publications co-authored by Mohamed Sayegh and Anil Chandraker.
Connection Strength

2.927
  1. Does belatacept provide equivalent suppression of acute renal transplant rejection to ciclosporin? Nat Clin Pract Nephrol. 2006 Mar; 2(3):134-5.
    View in: PubMed
    Score: 0.326
  2. Late blockade of T cell costimulation interrupts progression of experimental chronic allograft rejection. J Clin Invest. 1998 Jun 01; 101(11):2309-18.
    View in: PubMed
    Score: 0.191
  3. CD28-b7 blockade in organ dysfunction secondary to cold ischemia/reperfusion injury. Kidney Int. 1997 Dec; 52(6):1678-84.
    View in: PubMed
    Score: 0.184
  4. T-cell costimulatory blockade in experimental chronic cardiac allograft rejection: effects of cyclosporine and donor antigen. Transplantation. 1997 Apr 27; 63(8):1053-8.
    View in: PubMed
    Score: 0.177
  5. Deleterious effect of CTLA4-Ig on a Treg-dependent transplant model. Am J Transplant. 2012 Apr; 12(4):846-55.
    View in: PubMed
    Score: 0.123
  6. The novel costimulatory programmed death ligand 1/B7.1 pathway is functional in inhibiting alloimmune responses in vivo. J Immunol. 2011 Aug 01; 187(3):1113-9.
    View in: PubMed
    Score: 0.118
  7. Paradoxical functions of B7: CD28 costimulation in a MHC class II-mismatched cardiac transplant model. Am J Transplant. 2009 Dec; 9(12):2837-44.
    View in: PubMed
    Score: 0.105
  8. Critical role of donor tissue expression of programmed death ligand-1 in regulating cardiac allograft rejection and vasculopathy. Circulation. 2008 Feb 05; 117(5):660-9.
    View in: PubMed
    Score: 0.093
  9. The antagonism of calcineurin inhibitors and costimulatory blockers: fact or fiction? Transplant Proc. 2004 Mar; 36(2 Suppl):570S-573S.
    View in: PubMed
    Score: 0.071
  10. Interaction between ICOS-B7RP1 and B7-CD28 costimulatory pathways in alloimmune responses in vivo. Am J Transplant. 2003 Apr; 3(4):390-5.
    View in: PubMed
    Score: 0.067
  11. The role of the CD134-CD134 ligand costimulatory pathway in alloimmune responses in vivo. J Immunol. 2003 Mar 15; 170(6):2949-55.
    View in: PubMed
    Score: 0.066
  12. A novel CD154 monoclonal antibody in acute and chronic rat vascularized cardiac allograft rejection. Transplantation. 2002 Jun 15; 73(11):1736-42.
    View in: PubMed
    Score: 0.063
  13. Mechanisms of targeting CD28 by a signaling monoclonal antibody in acute and chronic allograft rejection. Transplantation. 2002 Apr 27; 73(8):1310-7.
    View in: PubMed
    Score: 0.063
  14. Indirect allorecognition of donor class I and II major histocompatibility complex peptides promotes the development of transplant vasculopathy. J Am Soc Nephrol. 2001 Nov; 12(11):2500-2506.
    View in: PubMed
    Score: 0.060
  15. Regulatory functions of self-restricted MHC class II allopeptide-specific Th2 clones in vivo. J Clin Invest. 2001 Apr; 107(7):909-16.
    View in: PubMed
    Score: 0.058
  16. CD28-B7-mediated T cell costimulation in chronic cardiac allograft rejection: differential role of B7-1 in initiation versus progression of graft arteriosclerosis. Am J Pathol. 2001 Mar; 158(3):977-86.
    View in: PubMed
    Score: 0.058
  17. Bacterial pathogens induce abscess formation by CD4(+) T-cell activation via the CD28-B7-2 costimulatory pathway. Infect Immun. 2000 Dec; 68(12):6650-5.
    View in: PubMed
    Score: 0.057
  18. In vitro and in vivo immunomodulatory effects of RDP1258, a novel synthetic peptide. J Am Soc Nephrol. 1999 Sep; 10(9):1997-2005.
    View in: PubMed
    Score: 0.052
  19. Accelerated Allograft Vasculopathy With Rituximab After Cardiac Transplantation. J Am Coll Cardiol. 2019 07 09; 74(1):36-51.
    View in: PubMed
    Score: 0.051
  20. P2X7R mutation disrupts the NLRP3-mediated Th program and predicts poor cardiac allograft outcomes. J Clin Invest. 2018 08 01; 128(8):3490-3503.
    View in: PubMed
    Score: 0.048
  21. Comparative strategies to induce long-term graft acceptance in fully allogeneic renal versus cardiac allograft models by CD28-B7 T cell costimulatory blockade: role of thymus and spleen. J Am Soc Nephrol. 1998 May; 9(5):891-8.
    View in: PubMed
    Score: 0.047
  22. Mechanisms of indirect allorecognition: characterization of MHC class II allopeptide-specific T helper cell clones from animals undergoing acute allograft rejection. Transplantation. 1998 Apr 15; 65(7):876-83.
    View in: PubMed
    Score: 0.047
  23. Chronic rejection from bedside to bench: role of T cells. Ann Transplant. 1997; 2(2):53-60.
    View in: PubMed
    Score: 0.043
  24. CD28-B7 T cell costimulatory blockade by CTLA4Ig in the rat renal allograft model: inhibition of cell-mediated and humoral immune responses in vivo. Transplantation. 1996 Dec 27; 62(12):1942-5.
    View in: PubMed
    Score: 0.043
  25. Blockade of T-cell costimulation prevents development of experimental chronic renal allograft rejection. Proc Natl Acad Sci U S A. 1996 Oct 29; 93(22):12439-44.
    View in: PubMed
    Score: 0.043
  26. Ex vivo treatment of antigen-presenting cells with CTLA4Ig and encephalitogenic peptide prevents experimental autoimmune encephalomyelitis in the Lewis rat. J Immunol. 1996 Oct 15; 157(8):3700-5.
    View in: PubMed
    Score: 0.043
  27. Live Images of Donor Dendritic Cells Trafficking via CX3CR1 Pathway. Front Immunol. 2016; 7:412.
    View in: PubMed
    Score: 0.043
  28. Imaging cell biology in transplantation. Transpl Int. 2016 Dec; 29(12):1349-1351.
    View in: PubMed
    Score: 0.042
  29. Cholesterol efflux capacity of high-density lipoprotein correlates with survival and allograft vasculopathy in cardiac transplant recipients. J Heart Lung Transplant. 2016 11; 35(11):1295-1302.
    View in: PubMed
    Score: 0.042
  30. The Limits of Linked Suppression for Regulatory T Cells. Front Immunol. 2016; 7:82.
    View in: PubMed
    Score: 0.041
  31. Multicenter Analysis of Immune Biomarkers and Heart Transplant Outcomes: Results of the Clinical Trials in Organ Transplantation-05 Study. Am J Transplant. 2016 Jan; 16(1):121-36.
    View in: PubMed
    Score: 0.039
  32. The programmed death-1 ligand 1:B7-1 pathway restrains diabetogenic effector T cells in vivo. J Immunol. 2011 Aug 01; 187(3):1097-105.
    View in: PubMed
    Score: 0.029
  33. Essential role of PDL1 expression on nonhematopoietic donor cells in acquired tolerance to vascularized cardiac allografts. Am J Transplant. 2011 Apr; 11(4):832-40.
    View in: PubMed
    Score: 0.029
  34. Endothelial-to-mesenchymal transition contributes to cardiac fibrosis. Nat Med. 2007 Aug; 13(8):952-61.
    View in: PubMed
    Score: 0.022
  35. Neural stem/progenitor cells express costimulatory molecules that are differentially regulated by inflammatory and apoptotic stimuli. Am J Pathol. 2004 May; 164(5):1615-25.
    View in: PubMed
    Score: 0.018
  36. Regulatory functions of alloreactive Th2 clones in human renal transplant recipients. Kidney Int. 2002 Aug; 62(2):627-31.
    View in: PubMed
    Score: 0.016
  37. Recipient MHC class II expression is required to achieve long-term survival of murine cardiac allografts after costimulatory blockade. J Immunol. 2001 Nov 15; 167(10):5522-6.
    View in: PubMed
    Score: 0.015
  38. Hepatocyte growth factor prevents the development of chronic allograft nephropathy in rats. J Am Soc Nephrol. 2001 Jun; 12(6):1280-1292.
    View in: PubMed
    Score: 0.015
  39. Role of passive T-cell death in chronic experimental autoimmune encephalomyelitis. J Clin Invest. 2000 Apr; 105(8):1109-16.
    View in: PubMed
    Score: 0.014
  40. CD28-B7 blockade prevents the development of experimental autoimmune glomerulonephritis. J Clin Invest. 2000 Mar; 105(5):643-51.
    View in: PubMed
    Score: 0.013
  41. Cognate stimulatory B-cell-T-cell interactions are critical for T-cell help recruited by glycoconjugate vaccines. Infect Immun. 1999 Dec; 67(12):6375-84.
    View in: PubMed
    Score: 0.013
  42. Anti-CD154 or CTLA4Ig obviates the need for thymic irradiation in a non-myeloablative conditioning regimen for the induction of mixed hematopoietic chimerism and tolerance. Transplantation. 1999 Nov 15; 68(9):1348-55.
    View in: PubMed
    Score: 0.013
  43. The role of B/T costimulatory signals in the immunopotentiating activity of neisserial porin. J Infect Dis. 1999 Sep; 180(3):755-61.
    View in: PubMed
    Score: 0.013
  44. Distinct tolerance pathways in sensitized allograft recipients after selective blockade of activation signal 1 or signal 2. Transplantation. 1999 Jul 27; 68(2):288-93.
    View in: PubMed
    Score: 0.013
  45. Regulatory T cells maintain peripheral tolerance to islet allografts induced by intrathymic injection of MHC class I allopeptides. Cell Transplant. 1999 Jul-Aug; 8(4):375-81.
    View in: PubMed
    Score: 0.013
  46. Role of peripheral clonal deletion in tolerance induction with bone marrow transplantation and costimulatory blockade. Transplant Proc. 1999 Feb-Mar; 31(1-2):680.
    View in: PubMed
    Score: 0.012
  47. Distinct tolerance pathways in sensitized rat recipients after blockade of activation signal 1 and signal 2. Transplant Proc. 1999 Feb-Mar; 31(1-2):876-7.
    View in: PubMed
    Score: 0.012
  48. Comparative studies of specific acquired systemic tolerance induced by intrathymic inoculation of a single synthetic Wistar-Furth (RT1U) allo-MHC class I (RT1.AU) peptide or WAG (RT1U)-derived class I peptide. Transplantation. 1998 Oct 27; 66(8):1059-66.
    View in: PubMed
    Score: 0.012
  49. Effects of explosive brain death on cytokine activation of peripheral organs in the rat. Transplantation. 1998 Jun 27; 65(12):1533-42.
    View in: PubMed
    Score: 0.012
  50. Extrathymic T cell deletion and allogeneic stem cell engraftment induced with costimulatory blockade is followed by central T cell tolerance. J Exp Med. 1998 Jun 15; 187(12):2037-44.
    View in: PubMed
    Score: 0.012
  51. CD4-targeted therapy and CD28-B7 costimulatory blockage may independently induce tolerance in sensitized allograft recipients. Transplant Proc. 1998 Jun; 30(4):1063-4.
    View in: PubMed
    Score: 0.012
  52. Role of regulatory T cells in the "infectious" tolerance pathway in transplant recipients. Transplant Proc. 1998 Feb; 30(1):13-5.
    View in: PubMed
    Score: 0.012
  53. Agonistic and antagonistic interactions between CTLA4Ig and donor alloantigens in sensitized rat recipients of cardiac allografts. Transplant Proc. 1998 Feb; 30(1):16-8.
    View in: PubMed
    Score: 0.012
  54. Differential effects of B7-1 blockade in the rat experimental autoimmune encephalomyelitis model. J Immunol. 1997 Nov 01; 159(9):4212-6.
    View in: PubMed
    Score: 0.011
  55. The role of the B7 costimulatory pathway in experimental cold ischemia/reperfusion injury. J Clin Invest. 1997 Sep 01; 100(5):1199-203.
    View in: PubMed
    Score: 0.011
  56. CD28-B7 T cell costimulatory blockade by CTLA4Ig in sensitized rat recipients: induction of transplantation tolerance in association with depressed cell-mediated and humoral immune responses. J Immunol. 1997 Aug 15; 159(4):1711-7.
    View in: PubMed
    Score: 0.011
  57. Inhibition of CD26/dipeptidyl peptidase IV activity in vivo prolongs cardiac allograft survival in rat recipients. Transplantation. 1997 May 27; 63(10):1495-500.
    View in: PubMed
    Score: 0.011
  58. Role of the CD28:B7 costimulatory interaction in alloimmune responses. Kidney Int Suppl. 1997 Mar; 58:S8-10.
    View in: PubMed
    Score: 0.011
  59. Inhibition of CD28-B7 T-cell costimulatory activation pathway affects intragraft cytokine and growth factor expression in chronic renal allograft rejection. Transplant Proc. 1997 Feb-Mar; 29(1-2):1038.
    View in: PubMed
    Score: 0.011
  60. Th2-type cytokines in the "infectious" tolerance pathway. Transplant Proc. 1997 Feb-Mar; 29(1-2):1290-1.
    View in: PubMed
    Score: 0.011
  61. CD28-B7 costimulatory blockade by CTLA4Ig prevents actively induced experimental autoimmune encephalomyelitis and inhibits Th1 but spares Th2 cytokines in the central nervous system. J Immunol. 1995 Nov 15; 155(10):4521-4.
    View in: PubMed
    Score: 0.010
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.